AstraZeneca PLC, a global biopharmaceutical company, has filed a Schedule 13G with the United States Securities and Exchange Commission (SEC) on October 11, 2024, indicating a significant stake in Conduit Pharmaceuticals Inc. According to the filing, AstraZeneca PLC, through its wholly-owned subsidiary AstraZeneca AB, has acquired 9,504,465 shares of Conduit Pharmaceuticals' common stock, representing 9.9% of the company. This level of ownership makes AstraZeneca one of the major shareholders of Conduit Pharmaceuticals. The shares are directly held by AstraZeneca AB, and both AstraZeneca PLC and AstraZeneca AB are deemed to have sole voting and dispositive power over these shares. The percentage ownership was calculated based on 96,004,699 shares of Conduit Pharmaceuticals' common stock outstanding as of August 12, 2024. The filing was made under Rule 13d-1(c) of the Securities Exchange Act of 1934, which is used by persons who have acquired beneficial ownership of more than five percent of a class of equity securities of a publicly-traded company.

AstraZeneca PLC, a global biopharmaceutical company, has filed a Schedule 13G with the United States Securities and Exchange Commission (SEC) on October 11, 2024, indicating a significant stake in Conduit Pharmaceuticals Inc. According to the filing, AstraZeneca PLC, through its wholly-owned subsidiary AstraZeneca AB, has acquired 9,504,465 shares of Conduit Pharmaceuticals' common stock, representing 9.9% of the company. This level of ownership makes AstraZeneca one of the major shareholders of Conduit Pharmaceuticals. The shares are directly held by AstraZeneca AB, and both AstraZeneca PLC and AstraZeneca AB are deemed to have sole voting and dispositive power over these shares. The percentage ownership was calculated based on 96,004,699 shares of Conduit Pharmaceuticals' common stock outstanding as of August 12, 2024. The filing was made under Rule 13d-1(c) of the Securities Exchange Act of 1934, which is used by persons who have acquired beneficial ownership of more than five percent of a class of equity securities of a publicly-traded company.